Core Viewpoint - Northeast Pharmaceutical (000597.SZ) is launching a shareholder reward program to express gratitude to shareholders and enhance their understanding of the company's intrinsic value while promoting its new beauty products [1] Group 1: Shareholder Reward Program - The company is initiating a "shareholder reward activity" to thank shareholders for their long-term support [1] - The program includes a dual surprise offer for eligible shareholders, which involves downloading the "Enterprise WeChat APP" and entering a company-specific WeChat group for identity verification [1] - Shareholders can unlock a "buy 1 get 4" offer on the company's proprietary "Qifangyuan" beauty product series, along with an exclusive 10% discount [1] Group 2: Promotional Details - The dual benefits are available from December 25, 2025, to December 28, 2025, exclusively on the company's authorized online store [1] - Each order is limited to one 10% discount coupon, which cannot be exchanged for cash or combined with other non-shareholder exclusive offers [1] - The discount coupon will automatically expire if not used within the specified period [1]

海南海药今日涨停，全天换手率29.43%，成交额29.66亿元，振幅4.29%。龙虎榜数据显示，机构净买入 1.28亿元，深股通净买入1.30亿元，营业部席位合计净卖出1672.42万元。 深交所公开信息显示，当日该股因日涨幅偏离值达10.02%上榜，机构专用席位净买入1.28亿元，深股通 净买入1.30亿元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交6.90亿元，其中，买入成交额为4.65亿 元，卖出成交额为2.25亿元，合计净买入2.41亿元。 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 深股通专用 | 19529.33 | 6564.83 | | 买二 | 机构专用 | 7509.36 | 4758.72 | | 买三 | 机构专用 | 7268.61 | 1843.52 | | 买四 | 国盛证券有限责任公司上海浦东新区世纪大道证券营业 | 5358.82 | 870.74 | | | 部 | | | | 买五 | 机构专用 | 4949.48 | 348.9 ...

康芝药业12月23日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 机构专用 | 6865.31 | 3104.25 | | 买二 | 机构专用 | 6230.60 | 2659.05 | | 买三 | 机构专用 | 5582.55 | 1359.67 | | 买四 | 机构专用 | 3646.63 | 120.29 | | 买五 | 中国银河证券股份有限公司北京中关村大街证券营业 | 3394.58 | 1204.24 | | | 部 | | | | 卖一 | 国泰海通证券股份有限公司成都北一环路证券营业部 | 36.08 | 9848.94 | | 卖二 | 国泰海通证券股份有限公司北京知春路证券营业部 | 220.69 | 8878.12 | | 卖三 | 开源证券股份有限公司西安西大街证券营业部 | 12.10 | 5678.61 | | 卖四 | 东方证券股份有限公司拉萨金珠西路证券营业部 | 0.00 | 4506.92 | | 卖五 | 机构专用 | 6865.31 | 3104.2 ...

Core Viewpoint - The company, Lianhuan Pharmaceutical (600513.SH), has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel (APIMF484, WHO API-484), has passed the WHO prequalification (PQ) process and is now included in the procurement scope of international organizations and public institutions [1] Group 1 - The product has successfully passed the WHO prequalification site inspection [1] - As of the date of this announcement, the Drug Master File (DMF) review for the product has also been completed [1] - The product is now fully prequalified by the WHO [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its raw material drug, Levonorgestrel, has passed the WHO prequalification, allowing it to be included in procurement by international organizations and public institutions [1] Group 1 - The company announced that its Levonorgestrel product is now recognized by the WHO, expanding its market potential [1] - The company's subsidiary, Changle Pharmaceutical, has received approval from the National Medical Products Administration for a supplemental application regarding Atropine Sulfate Injection, which includes the addition of a new specification of 1ml: 0.5mg [1] - The approval also pertains to the consistency evaluation of the quality and efficacy of the generic drug [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received notification from the World Health Organization (WHO) that its active pharmaceutical ingredient, Levonorgestrel, has passed the WHO prequalification process [1] Group 1: WHO Prequalification - The product Levonorgestrel has successfully undergone on-site inspection and the Drug Master File (DMF) review by the WHO, achieving full prequalification [1] - This prequalification is expected to enhance the company's credibility in the global market [1] Group 2: Financial Impact - The prequalification is not anticipated to have a significant impact on the company's current operating performance [1] - Future sales orders for the product remain uncertain, indicating potential variability in revenue generation [1]

Group 1 - The chemical pharmaceutical sector increased by 0.41% compared to the previous trading day, with Hongyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3919.98, up 0.07%, while the Shenzhen Component Index closed at 13368.99, up 0.27% [1] Group 2 - In terms of capital flow, the chemical pharmaceutical sector experienced a net outflow of 777 million yuan from main funds, while retail investors saw a net inflow of 859 million yuan [2] - The net outflow from speculative funds was 81.43 million yuan [2]

Core Viewpoint - The company has approved the use of up to 230 million yuan of idle raised funds for cash management, indicating a strategic approach to optimize financial resources [1] Group 1: Fund Management - On October 14, the company utilized 80 million yuan of idle raised funds to purchase a customized structured deposit product from China Construction Bank's Zhejiang branch [1] - The structured deposit product matured on December 22, with the company recovering the principal of 80 million yuan along with an interest income of 286,200 yuan, which was returned to the raised funds account [1] - The returns from the investment were in line with expectations, showing no significant discrepancies [1]

Group 1: Chemical Sector Performance - The chemical raw materials index increased by 1.62%, while the chemical machinery index decreased by 0.96%, the chemical pharmaceuticals index fell by 1.69%, and the pesticide and fertilizer index rose by 4.21% [1] - The top five rising petrochemical products included folic acid up by 20%, battery-grade lithium carbonate up by 11.08%, nitric acid up by 10.43%, sulfur up by 9.95%, and petroleum coke up by 7.23% [1] - The top five declining petrochemical products were liquid chlorine down by 34%, butadiene down by 7.69%, 2,4-D down by 6.09%, trichloroethylene down by 6.00%, and SBS down by 5.90% [1] Group 2: Oil Sector Performance - The oil processing index rose by 1.39%, while the oil extraction index fell by 0.22%, and the oil trading index increased by 3.44% [1] - International crude oil prices continued to decline, with West Texas Intermediate crude oil futures settling at $56.66 per barrel, down 1.36% from December 12, and Brent crude oil futures settling at $60.47 per barrel, down 1.06% from December 12 [1] Group 3: Capital Market Performance of Listed Chemical Companies - The top five rising listed chemical companies included Sulihua Co., Ltd. up by 30.69%, Xinri Hengli up by 27.48%, Reborn Technology up by 23.25%, Ruihua Tai up by 20.93%, and Shenjian Co., Ltd. up by 20.50% [2] - The top five declining listed chemical companies were Huarong Chemical down by 20.01%, Enjie Co., Ltd. down by 18.36%, Weike Technology down by 13.15%, Jinbantai down by 12.83%, and Xingye Co., Ltd. down by 12.63% [2]

Group 1 - The company has received approval from the U.S. FDA for its clinical trial application for the drug HS387, which is a selective KIF18A inhibitor intended for the treatment of advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer [1][1]. - The drug HS387 has been developed independently by the company and has also received clinical trial approval from the National Medical Products Administration of China [1][1]. - The clinical trial application for HS387 was submitted to the U.S. FDA in November 2025, and the approval was granted recently, marking a significant milestone in the drug's development process [1][1]. Group 2 - Currently, multiple KIF18A inhibitors are in the clinical research phase both domestically and internationally, but no drugs have been marketed yet [1][1].